BioCardia (NASDAQ: BCDA) posts CardiAMP CMI data with durable angina and exercise gains
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
BioCardia, Inc. reported preliminary open-label results from its CardiAMP Cell Therapy trial in chronic myocardial ischemia, presented at the EuroPCR conference. The minimally invasive, autologous cell therapy was well tolerated, with no treatment emergent major adverse cardiac events through two years of follow-up.
Patients had already exhausted guideline-directed medical, percutaneous, and surgical options before treatment. After CardiAMP therapy, average exercise tolerance increased by 179 seconds and this benefit persisted over two years. Angina episodes fell by an average of 82% by six months, suggesting meaningful symptom relief for severely symptomatic refractory angina patients.
Positive
- None.
Negative
- None.
Insights
Early CardiAMP CMI data show durable symptom improvements in a hard-to-treat angina population.
The update centers on preliminary open-label results from BioCardia’s CardiAMP Cell Therapy in chronic myocardial ischemia, a condition where patients often have no remaining revascularization options. The procedure is catheter-based and uses a patient’s own bone marrow cells, which may help reduce safety concerns tied to foreign cells.
In this small cohort, patients showed an average 179-second gain in exercise tolerance that persisted to two years, and an average 82% reduction in angina episodes by six months, with no treatment emergent major adverse cardiac events. While open-label data are inherently limited, these results support continued clinical development and align with the program’s FDA Breakthrough Therapy designation for ischemic heart failure.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Exercise tolerance improvement: 179 seconds
Angina reduction: 82% reduction
Follow-up duration: 2 years
+2 more
5 metrics
Exercise tolerance improvement
179 seconds
Average increase in exercise tolerance, persisting to two-year follow-up
Angina reduction
82% reduction
Average reduction in angina episodes by six months after treatment
Follow-up duration
2 years
Duration over which positive clinical outcomes were observed
Refractory angina prevalence (U.S.)
600,000–1.8 million patients
Estimated U.S. patients with chronic myocardial ischemia and refractory angina
Suboptimal revascularization candidates
Up to 15%
Share of ischemia/angina patients undergoing catheterization who are poor candidates for revascularization
Key Terms
refractory angina, guideline-directed medical therapy, Breakthrough Therapy, autologous cell therapy, +1 more
5 terms
refractory angina medical
"severely symptomatic refractory angina and validate continued clinical development"
Chronic chest pain caused by reduced blood flow to the heart that continues despite standard treatments such as medications, stents, or bypass surgery. Investors care because this unmet medical need drives demand for new drugs, medical devices, and procedures, affects healthcare spending and regulatory decisions, and can influence the commercial prospects and valuation of companies developing effective therapies — like a stubborn leak that needs a novel repair solution.
guideline-directed medical therapy medical
"all patients were on guideline-directed medical therapy and had received all available"
Guideline-directed medical therapy is the set of treatments doctors are recommended to use for a specific disease based on expert consensus and clinical evidence, like following a trusted recipe for best results. It matters to investors because whether a new drug or device becomes part of that standard affects how widely it will be adopted, how insurers pay for it, and how companies compare in clinical studies—factors that influence sales, regulatory success, and long-term value.
Breakthrough Therapy regulatory
"Designated by the FDA as a Breakthrough Therapy for Ischemic Heart Failure"
A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.
autologous cell therapy medical
"with the autologous cell therapy up through two years follow-up"
Autologous cell therapy uses a patient’s own cells, taken out, sometimes modified or multiplied, and then returned to the same person to treat disease or repair tissue. It matters to investors because using a person’s own cells can lower the chance of immune rejection and change the regulatory and clinical risk profile, but it also creates high, customized manufacturing and delivery costs and limits how easily the therapy can be scaled — like bespoke tailoring versus off‑the‑rack clothing.
allogeneic medical
"CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms"
Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.
FAQ
What did BioCardia (BCDA) report in its CardiAMP CMI trial update?
BioCardia reported preliminary open-label results from its CardiAMP Cell Therapy trial in chronic myocardial ischemia. The minimally invasive, autologous therapy was well tolerated, with no treatment emergent major adverse cardiac events and durable improvements in exercise tolerance and angina frequency over two years of follow-up.
How did CardiAMP Cell Therapy affect exercise tolerance in the BioCardia trial?
CardiAMP Cell Therapy increased exercise tolerance by an average of 179 seconds in treated patients. This improvement in exercise time persisted through the two-year study follow-up, suggesting sustained functional benefit for individuals with severely symptomatic refractory angina who had exhausted other treatment options.
What impact did BioCardia’s CardiAMP therapy have on angina episodes?
Patients treated with CardiAMP Cell Therapy experienced an average 82% reduction in angina episodes by six months. These patients had chronic myocardial ischemia with refractory angina despite guideline-directed medical therapy and available procedures, indicating meaningful symptom relief in a particularly challenging clinical population.
Who presented BioCardia’s CardiAMP CMI trial data at EuroPCR?
The CardiAMP CMI trial results were presented by Dr. Amish Raval, M.D., Professor of Medicine at the University of Wisconsin School of Medicine and Public Health. He presented on behalf of the CardiAMP CMI Investigators at EuroPCR, a leading interventional cardiovascular medicine conference in Paris.
What is the unmet need targeted by BioCardia’s CardiAMP CMI program?
CardiAMP targets chronic myocardial ischemia with refractory angina, affecting an estimated 600,000 to 1.8 million U.S. patients. Up to 15% of ischemia or angina patients undergoing catheterization are poor candidates for revascularization, leaving them with impaired quality of life and high healthcare utilization despite existing therapies.
How is BioCardia’s CardiAMP Cell Therapy program positioned from a regulatory perspective?
CardiAMP Cell Therapy has FDA Breakthrough Therapy designation for ischemic heart failure, reflecting its potential in serious cardiac disease. The program combines pre-procedural cell analysis, high target cell dosing, and a proprietary delivery system designed for safer intramyocardial delivery and improved cell retention in cardiac tissue.